Advised on Sale of Company

Healthcare

Xell AG

Provider of ultra-high-performance cell culture media and feeds Germany

has been acquired by

Sartorius AG

Leading international partner of the biopharmaceutical industry and life science research sector Germany

IMAP advises the shareholders of Xell AG on the sale to Sartorius

The shareholders of Xell AG, a specialist supplier of cell culture media, have sold their shares to Sartorius Stedim Biotech, a division of the listed life science company Sartorius.

Xell AG, Bielefeld, Germany

Xell AG, based in Bielefeld, Germany, provides ultra-high-performance culture media and feeds in particular for the production of viral vectors used in gene therapies and vaccines, since its foundation 12 years ago. In addition, the globally operating company offers various analytical services to characterize and quantify media components and optimize media formulations. Two years ago, the company invested in a very extensive and state-of-the-art production facility for powder and liquid culture media.

Sartorius AG, Göttingen, Germany

Sartorius is a leading international partner of the biopharmaceutical industry and life science research sector. By acquiring complementary technologies, Sartorius AG regularly extends its portfolio in the areas of "Lab Products & Services" and "Bioprocess Solutions". During 2020, the company generated revenues of approx. 2.3 billion euros. By the end of 2020 the group employed nearly 11,000 people in more than 110 countries.

 

The IMAP team exclusively advised the shareholders of Xell AG and supported them in preparing, negotiating and successfully closing the transaction.

SEE DEAL BRIEF